← Product Code [GEX](/productcode/GEX) · K223404
# Duetto Suprema; Domino Suprema; Suprema VT; Suprema VT+; Suprema 4V (K223404)
_Quanta System Spa · GEX · Jan 20, 2023 · General, Plastic Surgery · SESE_
**Canonical URL:** https://fda-staging.innolitics.com/device/K223404
## Device Facts
- **Applicant:** Quanta System Spa
- **Product Code:** [GEX](/productcode/GEX.md)
- **Decision Date:** Jan 20, 2023
- **Decision:** SESE
- **Submission Type:** Special
- **Regulation:** 21 CFR 878.4810
- **Device Class:** Class 2
- **Review Panel:** General, Plastic Surgery
- **Attributes:** Therapeutic
## Indications for Use
Suprema Family is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows. 1064 nm (pulsed) Dermatology/Plastic Surgery: Intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratoses, nevi, chloasma, verrucae, skin tags, keratosis and plaques. The laser is also indicated for the treatment of wrinkles such as, but not limited to, periocular and perioral wrinkles. The laser is also indicated for the treatment of facial wrinkles. Additionally, the laser is indicated for the treatment of pseudofolliculitis barbae (PFB) and for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs regrowing when measured at 6, 9 and 12 months after the completion of a treatment regime. It is indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. The laser is also indicated for pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. It is indicated for use on all skin types (Fitzpatrick I-VI) including tanned skin, and the removal and permanent reduction of unwanted hair in Fitzpatrick I-VI, including suntanned skin types. 532 nm (pulsed) Intended for the coagulation and hemostasis of vascular lesions. Dermatology/Plastic Surgery: For photocoagulation and hemostasis of vascular and cutaneous lesions in dermatology including but not limited to the following general categories: vascular lesions [angiomas, hemangiomas (port wine), telangiectasia (facial or ex-tremities telangiectasias, venous anomalies, leg veins]; benign pigmented lesions (nevi, lentigines, chloasma, cafe au- lait, tattoos (red and green ink), verrucae, skin tags, keratoses, plaques, cutaneous lesion treatment (hemostasis, color lightening, flattening, reduction of lesion size). 755 nm (pulsed) Indicated for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs re-growing when measured 6, 9, or 12 months after the completion of a treatment regime. It is used for all skin types (Fitzpatrick I-VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles. IPL 590-1200nm; 625-1200nm; 650-1200nm Indicated for permanent hair removal. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. IPL 550-1200nm: 570-1200nm Indicated for photocoagulation of dermatological vascular lesion (i.e. face telangiectasia), photothermolysis of blood vessels (treatment of facial and leg veins), and treatment of benign pigmented lesions. IPL 400-1200nm Indicated for inflammatory acne (acne vulgaris). Integrated Skin Cooler The intended use of the integrated cooling system in Suprema Family is to provide cooling of the skin prior to laser treatment, for the reduction of pain during laser treatment, to allow for the use of higher fluences for laser treatments such as hair removal and vascular lesion, and to reduce the potential side effects of laser treatments.
## Device Story
Suprema Family consists of transportable medical laser devices (Nd:YAG 1064nm, 532nm; Alexandrite 755nm) and optional IPL accessories; used by dermatologists in professional healthcare environments. Inputs: laser energy delivered via optical fibers to handpieces. Operation: device includes power electronics, control electronics (microcontroller), cooling system, and optical bench. Integrated skin cooler or external Cryo 6 (Zimmer) provides epidermal cooling to reduce pain and side effects, allowing higher fluences. Activation via footswitch or handpiece finger-switch. Output: laser/IPL radiation for soft tissue interaction (coagulation, ablation, etc.). Healthcare providers use the GUI to select parameters; output affects clinical decision-making by enabling targeted treatment of dermatological conditions. Benefits include precise tissue management and permanent hair reduction.
## Clinical Evidence
Bench testing only. Compliance with IEC 60601-1, IEC 60601-1-2, IEC 60601-1-6, IEC 62366-1, IEC 62304, IEC 60601-2-22, IEC 60825-1, IEC 60601-2-57, and ISO 10993-1. Testing confirmed safety and effectiveness of the device modifications, including enclosure, handpieces, GUI, and software/firmware updates.
## Technological Characteristics
Laser surgical instrument (Class II, GEX). Sources: Nd:YAG (1064nm, 532nm), Alexandrite (755nm), and IPL (400-1200nm). Features integrated skin cooling system. Connectivity: GUI-based interaction. Software: Firmware-based control. Sterilization: Not specified (standard clinical cleaning). Materials: Metal tip parts (ISO 10993-1 compliant).
## Regulatory Identification
(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
## Predicate Devices
- Evo Platform ([K192160](/device/K192160.md))
- Chrome ([K202503](/device/K202503.md))
## Reference Devices
- Cryo 6 skin cooler ([K060395](/device/K060395.md))
- Twain 2940 ([K173002](/device/K173002.md))
## Submission Summary (Full Text)
> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a smaller font.
January 20, 2023
Quanta System, S.p.A. Dario Bandiera Regulatory Affairs Manager Via Acquedotto 109 Samarate, VA 21017 Italy
Re: K223404
Trade/Device Name: Duetto Suprema: Domino Suprema: Suprema VT+; Suprema VT+; Suprema 4V Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX Dated: November 2, 2022 Received: November 9, 2022
Dear Dario Bandiera:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
# Jianting Wang -S
Jianting Wang Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
Submission Number (if known)
| Device Name |
|--------------------------------|
| Duetto Suprema; |
| Domino Suprema; |
| Suprema VT; |
| Suprema VT+; |
| Suprema 4V |
| Indications for Use (Describe) |
General intended use
Suprema Family is intended for use in aesthetic, cosmetic and surgical applications requiring incision, excision, ablation, vaporization and coagulation of body soft tissues in the medical specialties of dermatology, general, plastic and oral surgery as follows.
Indications for use
1064 nm (pulsed)
Dermatology/Plastic Surgery:
Intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis.
The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratoses, nevi, chloasma, verrucae, skin tags, keratosis and plaques.
The laser is also indicated for the treatment of wrinkles such as, but not limited to, periocular and perioral wrinkles.
The laser is also indicated for the treatment of facial wrinkles.
Additionally, the laser is indicated for the treatment of pseudofolliculitis barbae (PFB) and for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs regrowing when measured at 6, 9 and 12 months after the completion of a treatment regime.
It is indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar.
The laser is also indicated for pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.
It is indicated for use on all skin types (Fitzpatrick I-VI) including tanned skin, and the removal and permanent reduction of unwanted hair in Fitzpatrick I-VI, including suntanned skin types.
532 nm (pulsed)
Intended for the coagulation and hemostasis of vascular lesions.
Dermatology/Plastic Surgery:
For photocoagulation and hemostasis of vascular and cutaneous lesions in dermatology including but not limited to the following general categories: vascular lesions [angiomas, hemangiomas (port
{3}------------------------------------------------
wine), telangiectasia (facial or ex-tremities telangiectasias, venous anomalies, leg veins]; benign pigmented lesions (nevi, lentigines, chloasma, cafe au- lait, tattoos (red and green ink), verrucae, skin tags, keratoses, plaques, cutaneous lesion treatment (hemostasis, color lightening, flattening, reduction of lesion size).
755 nm (pulsed)
Indicated for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs re-growing when measured 6, 9, or 12 months after the completion of a treatment regime. It is used for all skin types (Fitzpatrick I-VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles.
IPL 590-1200nm; 625-1200nm; 650-1200nm
Indicated for permanent hair removal.
Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime.
IPL 550-1200nm: 570-1200nm
Indicated for photocoagulation of dermatological vascular lesion (i.e. face telangiectasia), photothermolysis of blood vessels (treatment of facial and leg veins), and treatment of benign pigmented lesions.
IPL 400-1200nm Indicated for inflammatory acne (acne vulgaris).
Integrated Skin Cooler
The intended use of the integrated cooling system in Suprema Family is to provide cooling of the skin prior to laser treatment, for the reduction of pain during laser treatment, to allow for the use of higher fluences for laser treatments such as hair removal and vascular lesion, and to reduce the potential side effects of laser treatments.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
ver-The-Counter Use (21 CFR 801 Subpart C)
## CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.
{4}------------------------------------------------
# 510(k) Summary
| Applicant /
manufacturer: | Quanta System S.p.A., Via Acquedotto 109, 21017
Samarate (VA), Italy |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact person: | Dario Bandiera
RA Manager
Quanta System S.p.A.
Email: dario.bandiera@quantasystem.com
Phone: +39-0331-376797 |
| Date Prepared: | 2nd November 2022 |
| Model name: | Suprema Family including the following models:
Duetto Suprema, Suprema VT, Suprema VT+,
Suprema 4V, Domino Suprema. |
| Classification: | Class II |
| Classification Name: | Laser surgical instrument for use in general and
plastic surgery and in dermatology. |
| Regulation Number: | 21 CFR 878.4810 |
| Product Code: | GEX |
| Basis for submission: | Device technical modifications |
| Predicate device | Evo Platform (K192160) and Chrome (K202503)
manufactured by Quanta System. Suprema family
devices are derived from legally marketed Evo
Platform devices except for Twain IPL accessory that
is the same of Chrome family. |
{5}------------------------------------------------
# 1 Abbreviations
FW= firmware GUI= graphical user interface IPL= intense pulsed light P= pulsed SW= software
#### Device description 2
Suprema family includes medical laser devices for dermatology and aesthetic medicine. It is used by health care professionals (dermatologists) in professional healthcare environments for the treatment of different skin conditions and hair removal.
Suprema models differ for the installed laser sources only according to Table 1.
| | Nd: YAG 1064
nm (P*) | Nd: YAG 532 nm
(P*) | Alexandrite 755
nm (P*) |
|----------------|-------------------------|------------------------|----------------------------|
| Duetto Suprema | x | | x |
| Domino Suprema | | | x |
| Suprema VT | x | | |
| Suprema VT+ | x | x | |
| Suprema 4V | x | x | x |
Table 1: Suprema family models with laser sources (*P=Pulsed mode).
Suprema devices are transportable mobile electrical equipment with a graphical user interface (GUI) for user-device interaction.
Laser radiation is delivered through optical fibers connected to handpieces having fix or variable spot dimension.
The device can be optionally equipped with an integrated skin cooler. In this case, a specific housing called Skin Cooler handpiece is provided to provide skin cooling the laser handpiece at the same time. Configurations without optional integrated skin cooler, can be used in conjunction with Cryo 6 skin cooler manufactured by Zimmer GmbH (K060395). In this case, an optional housing is provided which is called Skin Cryo handpiece. Laser handpieces cannot be used alone but only in conjunction to Skin Cooler and Skin Cryo handpieces.
Laser emission can be activated by the footswitch or by a finger-switch placed on Skin Cooler and Skin Cryo handpieces.
The device can be divided into four main sections:
- Power electronics: they manage power supplied to all device compartments; -
- । Control electronics: they mainly consist of a microcontroller board where device main FW (firmware) is resident;
- -Cooling system: it cools the laser source pumping chamber and, in case of integrated skin cooling, a part of the water circulating in the hydraulic system is deviated to a chiller that cools water for skin cooling;
- -Optical bench.
Suprema devices can be used in conjunction with Twain 2940 devices. Twain IPL and Twain 2940 are already FDA cleared (K202503, K173002, respectively).
{6}------------------------------------------------
#### Comparison with the predicate ന
Suprema Family is equivalent to Evo family according to the cross-reference matrix below (Table 2), as they share the same laser wavelengths.
| Suprema | Evo | Sources (nm) |
|----------------|--------------|--------------------|
| Duetto Suprema | Light A Star | 1064, 755 (P) |
| Suprema VT | Light B | 1064 (P) |
| Suprema VT+ | Light C | 1064, 532 (P) |
| Suprema 4V | Light 4V | 1064, 532, 755 (P) |
| Domino Suprema | Domino | 755 (P) |
#### Table 2: Suprema vs Evo cross-reference matrix.
Suprema Family is equivalent to Evo family except for Twain IPL accessory that is identical to Chrome Twain IPL (K202503) which has been considered as further predicate.
In Table 3, the main specifications of the subject device are summarized and compared to the predicates:
| Specification | Predicate | Subject device |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Device Name | Evo Platform | Suprema Family |
| K number | K192160 | |
| Manufacturer | Quanta System S.p.A. | Quanta System S.p.A. |
| Product Code | GEX | GEX |
| Laser Sources | Nd:YAG and Alexandrite | Nd:YAG and Alexandrite |
| Laser Wavelengths | ☒ 1064nm pulsed
☒ 532nm pulsed
☒ 755nm pulsed | ☒ 1064nm pulsed
☒ 532nm pulsed
☒ 755nm pulsed |
| Indications for use | General intended use:
Suprema Family is intended for use in aesthetic, cosmetic and
surgical applications requiring incision, excision, ablation,
vaporization and coagulation of body soft tissues in the medical
specialties of dermatology, general, plastic and oral surgery as
follows.
Indications for use:
1064 nm (pulsed)
Dermatology/Plastic Surgery:
Intended for the coagulation and hemostasis of benign vascular
lesions such as, but not limited to, port wine stains, hemangiomas,
warts, telangectasia, rosacea, venus lake, leg veins, spider veins and
poikiloderma of civatte; and treatment of benign cutaneous lesions
such as warts, scars, striae and psoriasis.
The laser is also intended for the treatment of benign pigmented
lesions such as, but not limited to, lentigos (age spots), solar
lentigos (sun spots), cafe au lait macules, seborrheic keratoses,
nevi, chloasma, verrucae, skin tags, keratosis and plaques.
The laser is also indicated for the treatment of wrinkles such as, but
not limited to, periocular and perioral wrinkles. | The same |
#### Table 3: Main specifications comparison table.
{7}------------------------------------------------
| Specification
Device Name | Predicate | Subject device | | | |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| | Evo Platform | Suprema Family | | | |
| | Additionally, the laser is indicated for the treatment of
pseudofolliculitis barbae (PFB) and for stable long-term, or
permanent hair reduction. Permanent hair reduction is defined as
long-term stable reduction in the number of hairs regrowing when
measured at 6, 9 and 12 months after the completion of a
treatment regime. | | | | |
| | It is indicated for the reduction of red pigmentation in hypertrophic
and keloid scars where vascularity is an integral part of the scar.
The laser is also indicated for pigmented lesions to reduce lesion
size, for patients with lesions that would potentially benefit from
aggressive treatment, and for patients with lesions that have not
responded to other laser treatments. | | | | |
| | It is indicated for use on all skin types (Fitzpatrick I-VI) including
tanned skin, and the removal and permanent reduction of
unwanted hair in Fitzpatrick I-VI, including suntanned skin types. | | | | |
| | 532 nm (pulsed)
Intended for the coagulation and hemostasis of vascular lesions. | | | | |
| | Dermatology/Plastic Surgery:
For photocoagulation and hemostasis of vascular and cutaneous
lesions in dermatology including but not limited to the following
general categories: vascular lesions [angiomas, hemangiomas (port
wine), telangiectasia (facial or ex-tremities telangiectasias, venous
anomalies, leg veins]; benign pigmented lesions (nevi, lentigines,
chloasma, cafe au- lait, tattoos (red and green ink), verrucae, skin
tags, keratoses, plaques, cutaneous lesion treatment (hemostasis,
color lightening, blanching, flattening, reduction of lesion size). | | | | |
| | 755 nm (pulsed)
Indicated for stable long-term, or permanent hair reduction.
Permanent hair reduction is defined as long-term stable reduction
in the number of hairs re-growing when measured 6, 9, or 12
months after the completion of a treatment regime. It is used for
all skin types (Fitzpatrick I-VI) including tanned skin. It is also
indicated for the treatment of vascular lesions, benign pigmented
lesions, and wrinkles. | | | | |
| | IPL 590-1200nm; 625-1200nm; 650-1200nm
Indicated for permanent hair removal.
Permanent hair reduction is defined as the long-term, stable
reduction in the number of hairs regrowing when measured at 6, 9,
and 12 months after the completion of a treatment regime. | | | | |
| | IPL 550-1200nm; 570-1200nm
Indicated for photocoagulation of dermatological vascular lesion
(i.e. face telangiectasia), photothermolysis of blood vessels
(treatment of facial and leg veins), and treatment of benign
pigmented lesions. | | | | |
| | IPL 400-1200nm
Indicated for inflammatory acne (acne vulgaris). | | | | |
| | | Integrated Skin Cooler:
The intended use of the integrated cooling system in Suprema
Family is to provide cooling of the skin prior to laser treatment, for
the reduction of pain during laser treatment, to allow for the use of
higher fluences for laser treatments such as hair removal and | higher fluences for laser treatments such as hair removal and
vascular lesion, and to reduce the potential side effects of laser
treatments. | | |
| Pulse width (max) | @1064 nm: 300 ms
@532 nm: 50 ms | The same | | | |
{8}------------------------------------------------
| Specification | Predicate | Subject device |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name | Evo Platform | Suprema Family |
| Fluence (max) | @755 nm: 300 ms | The same |
| | @1064 nm: 300 J/cm² | |
| | @532 nm: 95 J/cm² | |
| | @755 nm: 60 J/cm² | |
| Spot Size | Handpieces spot diameter cleared with K192160 are:
@1064 nm: 2÷24 mm
@532 nm: 2÷7 mm
@755 nm: 6÷24 mm
Spots that have been actually placed on the market are the
following:
@1064 nm: 2÷5, 6, 8, 10, 12, 14, 16
@532 nm: 2÷5, 6, 7
@755 nm: 6, 8, 10, 12, 14, 16 | Variable:
2÷6 mm (1 mm step)
8÷20 mm (2 mm step) Fixed:
14, 16, 18, 20, 22 mm
The indicated sizes refer to
the diameter (in case of round
spots) or side (in case of
square spots).
At 1064 and 755 nm, the
maximum cleared (Evo) spot
area is:
A= $π*(24 mm/2)^2$ = 452 mm²
While the maximum area of
the subject device at all the
wavelengths is:
A=22*22 mm=484 mm²
At 1064 nm and 755 nm the
maximum spot area of the
subject device is 7% larger
than the maximum spot area
of the predicate device. The
difference is not significant
and does not raise any new
concern related to thermal
effects, considering also that
both the maximum energy
and fluence available for the
spot with larger sizes are
lower than the ones available
for the spots with the smaller
sizes (see Table 4).
For 532 nm the maximum
spot area of the subject
device is about 12 times the
maximum spot area of the
predicate device.
The difference does not raise
any new concern related to
thermal effects considering
that the maximum fluence
available for the spot with the
largest size is 28 times lower
than the fluence available for
the 4 mm spot (see Table 4).
Thus, the possible thermal
effect due to the pooling of
the heat in the center of the
large spot does not exceed
the thermal effect directly
reached through the
significantly higher fluence in
the small spot. The maximum |
| Specification | Predicate | Subject device |
| Device Name | Evo Platform | Suprema Family |
| | | fluence available in the small |
| | | spots is the same of the |
| | | predicate device. |
| Repetition Rate
(max) | @1064 nm: 10 Hz
@532 nm: 5 Hz
@755 nm: 10 Hz | The same |
| Skin Cooling | Three cooling levels | The same |
| Twain IPL | | |
| Specification | Predicate | Subject device |
| Device Name | Chrome | Suprema Family |
| K number | K202503 | - |
| Manufacturer | Quanta System S.p.A. | Quanta System S.p.A. |
| | 650-1200 nm | The same…
---
**Source:** [https://fda-staging.innolitics.com/device/K223404](https://fda-staging.innolitics.com/device/K223404)
**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).
**Cite:** Innolitics at https://innolitics.com